search
Back to results

A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers

Primary Purpose

Human Immunodeficiency Virus Infection

Status
Active
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
SHR2150 tablet、efavirenz
Sponsored by
Jiangsu HengRui Medicine Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Human Immunodeficiency Virus Infection

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. The subject can communicate well with the researcher, understand and comply with the requirements of this study, and understand and sign the informed consent;
  2. Healthy subjects aged 18 ~ 45 (including the boundary value), male and female;
  3. Male body weight ≥ 50 kg, female body weight ≥ 45 kg, body mass index (BMI) within the range of 18 ~ 26 kg/m2 (including the boundary value) (BMI= weight (kg)/height 2 (m2));
  4. The physical examination, vital signs, laboratory examination, 12-lead electrocardiogram, abdominal B-ultrasound, and chest radiograph are normal or have no clinical significance;
  5. The subjects with reproduction ability must agree to take effective contraceptive measures after signing the informed consent form and within 7 months (for female) or 4 months (for male) until the last medication.

Exclusion Criteria:

  1. Anyone who has suffered from any clinical serious disease such as the circulatory system, endocrine system, nervous system, digestive system, respiratory system, urogenital system, hematology, immunology, psychiatry and metabolic abnormalities, or any other disease which can affect the study results;
  2. Those who have undergone surgery within 3 months before the trial, or plan to perform surgery during the study period;
  3. Those whose 12-lead ECG is abnormal with clinically significant or ECG QT interval (QTcF) ≥ 450 ms (for male) or > 460 ms (for female) or < 300 ms;
  4. Those who donated blood or suffered heavy blood loss (≥400 mL), received blood transfusions, or used blood products within 3 months before enrollment;
  5. Have a history of allergies to drugs, food or other substances;
  6. Those who have used soft drugs or hard drugs; or those with positive results in urine drug abuse screening;
  7. Those who have participated in any clinical trials and have taken study drugs within 3 months before the first administration;
  8. Those who have taken any medicine within 1 month before the first administration (including prescription medicines, non-prescription medicines, Chinese herbal medicines, vitamins, calcium tablets and other food supplements), especially the drugs which have any effect on CYP3A4;
  9. Regular drinkers within 3 months before the test, that is, drinking more than 15 g of alcohol per day (15 g alcohol = 450 mL of beer, or 50 mL of spirits, or 150 mL of wine), and any alcohol-containing products cannot be stopped during the study;
  10. Hepatitis B virus surface antigen is positive, or hepatitis C virus antibody is positive, or treponema pallidum antibody is positive, or human immunodeficiency virus antibody is positive;
  11. Women with pregnancy or within lactation period.

Sites / Locations

  • The People's Hospital of Liaoning Province

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment group

Arm Description

SHR2150+ efavirenz

Outcomes

Primary Outcome Measures

Tmax
Time to maximum observed serum concentration (Tmax) for SHR2150 after Single dose
Cmax
Maximum observed serum concentration (Cmax) for SHR2150 after Single dose
AUC0-t
Area under the plasma concentration versus time curve (AUC0-t) for SHR2150 after Single dose
AUC0-inf
Area under the plasma concentration versus time curve (AUC0-inf ) for SHR2150 after Single dose
T1/2
Time to elimination half-life (T1/2) for for SHR2150 after Single dose

Secondary Outcome Measures

Number of subjects with adverse events and the severity of adverse events

Full Information

First Posted
November 19, 2021
Last Updated
December 17, 2021
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05141422
Brief Title
A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers
Official Title
A Single-centre, Single-arm, Open-label and Fixed-sequence Drug-drug Interaction Study to Evaluate the Effect of Efavirenz on the Pharmacokinetics of SHR2150 in Healthy Chinese Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
December 2021
Overall Recruitment Status
Active, not recruiting
Study Start Date
December 13, 2021 (Actual)
Primary Completion Date
January 15, 2022 (Anticipated)
Study Completion Date
January 22, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Jiangsu HengRui Medicine Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The study is a single-centre, open-label, fixed-sequence, self-controlled clinical trial. It is planned to enroll 20 healthy adult subjects. Subjects will take SHR2150 on Day 1 and Day 21, and take efavirenz from Day 7 to Day 26.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Human Immunodeficiency Virus Infection

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Model Description
The study is a single-centre, single-arm, open-label and fixed-sequence clinical trial.
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment group
Arm Type
Experimental
Arm Description
SHR2150+ efavirenz
Intervention Type
Drug
Intervention Name(s)
SHR2150 tablet、efavirenz
Intervention Description
SHR2150 tablet single dose, Efavirenz single dose.
Primary Outcome Measure Information:
Title
Tmax
Description
Time to maximum observed serum concentration (Tmax) for SHR2150 after Single dose
Time Frame
from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose
Title
Cmax
Description
Maximum observed serum concentration (Cmax) for SHR2150 after Single dose
Time Frame
from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose
Title
AUC0-t
Description
Area under the plasma concentration versus time curve (AUC0-t) for SHR2150 after Single dose
Time Frame
from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose
Title
AUC0-inf
Description
Area under the plasma concentration versus time curve (AUC0-inf ) for SHR2150 after Single dose
Time Frame
from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose
Title
T1/2
Description
Time to elimination half-life (T1/2) for for SHR2150 after Single dose
Time Frame
from Day 1 to Day 7 after the first dose and from Day 21 to Day 27 after the second dose
Secondary Outcome Measure Information:
Title
Number of subjects with adverse events and the severity of adverse events
Time Frame
from Day 1 to Day 37 after the first dose

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: The subject can communicate well with the researcher, understand and comply with the requirements of this study, and understand and sign the informed consent; Healthy subjects aged 18 ~ 45 (including the boundary value), male and female; Male body weight ≥ 50 kg, female body weight ≥ 45 kg, body mass index (BMI) within the range of 18 ~ 26 kg/m2 (including the boundary value) (BMI= weight (kg)/height 2 (m2)); The physical examination, vital signs, laboratory examination, 12-lead electrocardiogram, abdominal B-ultrasound, and chest radiograph are normal or have no clinical significance; The subjects with reproduction ability must agree to take effective contraceptive measures after signing the informed consent form and within 7 months (for female) or 4 months (for male) until the last medication. Exclusion Criteria: Anyone who has suffered from any clinical serious disease such as the circulatory system, endocrine system, nervous system, digestive system, respiratory system, urogenital system, hematology, immunology, psychiatry and metabolic abnormalities, or any other disease which can affect the study results; Those who have undergone surgery within 3 months before the trial, or plan to perform surgery during the study period; Those whose 12-lead ECG is abnormal with clinically significant or ECG QT interval (QTcF) ≥ 450 ms (for male) or > 460 ms (for female) or < 300 ms; Those who donated blood or suffered heavy blood loss (≥400 mL), received blood transfusions, or used blood products within 3 months before enrollment; Have a history of allergies to drugs, food or other substances; Those who have used soft drugs or hard drugs; or those with positive results in urine drug abuse screening; Those who have participated in any clinical trials and have taken study drugs within 3 months before the first administration; Those who have taken any medicine within 1 month before the first administration (including prescription medicines, non-prescription medicines, Chinese herbal medicines, vitamins, calcium tablets and other food supplements), especially the drugs which have any effect on CYP3A4; Regular drinkers within 3 months before the test, that is, drinking more than 15 g of alcohol per day (15 g alcohol = 450 mL of beer, or 50 mL of spirits, or 150 mL of wine), and any alcohol-containing products cannot be stopped during the study; Hepatitis B virus surface antigen is positive, or hepatitis C virus antibody is positive, or treponema pallidum antibody is positive, or human immunodeficiency virus antibody is positive; Women with pregnancy or within lactation period.
Facility Information:
Facility Name
The People's Hospital of Liaoning Province
City
Shenyang
State/Province
Liaoning
ZIP/Postal Code
110067
Country
China

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers

We'll reach out to this number within 24 hrs